RadNet is now offering the newest FDA-approved PET/CT tracer for prostate cancer.
Patients who elect for the Tulsa-Pro procedure will also have the opportunity to participate in the Customized TULSA-PRO Ablation Registry (CARE Registry) trial.
A registry is a place where medical information related to your prostate cancer treatment is collected and stored for the purpose of conducting medical research.
Upon graduating from medical school at New York Medical College after induction into the Alpha Omega Alpha honor society, Dr. Desai went on to complete a radiology residency at University of California, Los Angeles. Thereafter, she went on to complete a combined fellowship in Breast and Abdominal Imaging at the University of Southern California.
Dr. Neal Bost is a board-certified radiologist specializing in Body Imaging and Nuclear Radiology.
He attended Tulane University in New Orleans, LA for undergraduate (BS, Neuroscience), graduate (MS, Pharmacology), and medical school. He then completed Diagnostic Radiology residency at Kaiser Permanente Los Angeles Medical Center, followed by fellowship training in Nuclear Medicine & Molecular Imaging at LAC+USC Medical Center.
Joshua Friedlander, M.D., was born and raised in Agoura Hills, CA. He graduated with honors from the University of California, Davis with a degree in Neurobiology, Physiology and Behavior. After completing medical school at Rush medical College in Chicago, he began his radiology residency at Beaumont Health System in Royal Oak, Michigan.
Our very own Dr. Robert Princenthal presented on the TULSA Procedure prostate treatment at the AdMeTech Foundation's 5th Global Summit titled "Precision Diagnosis and Treatment of Prostate Cancer".
According to Dr. Robert Princenthal, Medical Director for RadNet’s Prostate MRI Program, this study is part of the growing evidence to support what he calls the “man-o-gram,” or as he explains, “prostate MRI plus PSA screening (a blood test not offered at our locations, but available at a local lab through your referring physician), in order to optimize early detection.”
RadNet’s Research Division has been participating in two clinical trials of a prostate-specific Positron Emission Tomography (PET) tracer in men with newly diagnosed prostate cancer and those with a recurrence of prostate cancer after having undergone previous prostate cancer treatment. Under the guidance of Judith Rose M.D., Medical Director of PET/CT and Clinical Research for RadNet, and in conjunction with Dr. David Josephson M.D. of Tower Urology, and Blue Earth Diagnostics.